MRI imaging drugs produced by GE Healthcare (GE) and Covidien appear to have a higher risk of a serious skin disease than similar products, advisers to the US Food and Drug Administration (FDA) said.
The panel of advisers said that GE’s Omniscan and Covidien’s Optimark should carry a warning that they should not be used in patients with severe kidney cancer, Reuters reports.
The drugs are gadolinium-based contrast agents and already carry warnings that patients are at risk from nephrogenic systemic fibrosis, which can lead to a thickening of organs and skin.
The FDA will now consider the advice, according to Reuters.
Share this article
